Evidence map›Paper›PMID 41029360›Full record

ArticleHereditas2025

Integrated single-cell and bulk transcriptome analysis revealed high plasticity subpopulation and promising diagnosis model for clear cell renal cell carcinoma.

Zhongwen Lu, Fanyi Kong, Jiahuan Sun, Jing Ge, Jiajin Wu, Kunpeng Wang

Abstract read
In one paragraph

Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhongwen Lu *Department of Urology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Fanyi Kong *Department of Urology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Jiahuan Sun *Department of Urology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Jing GeDepartment of Urology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China.
Jiajin WuKey Laboratory of Environmental Medicine Engineering, School of Public Health, Ministry of Education of China, Southeast University, Nanjing, China. wujiajin@seu.edu.cn.ORCID http://orcid.org/0000-0001-8880-8706
Kunpeng WangDepartment of Urology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu, China. wangkunpeng@xzhmu.edu.cn.ORCID http://orcid.org/0000-0001-8343-6464

Funding

General Science and Technology Project of Lianyungang City Health 202409Lianyungang First People's Hospital Key Talent Development Fund zdrc045Xuzhou Medical University Affiliated Hospital Development Fund Project XYFM202456
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is a highly heterogeneous tumor that lacks reliable biological markers for diagnosis and prognostic monitoring. Currently, the differentially expressed genes between paired adjacent normal tissues and ccRCC tumor tissues at single-cell resolution remained to be further discovered. To address this challenge, we performed an integrative analysis of multiple single-cell databases containing paired ccRCC samples. Using the "CopyKAT" algorithm, we accurately identified ccRCC tumor cells. Subsequently, various pseudotime algorithms were employed to identify malignant cells with tumor stem cell-like properties and high plasticity. This cell subgroup exhibited high expression of malignant features, including hypoxia, epithelial-mesenchymal transition (EMT), and proliferation/invasion phenotypes. We then performed differential analysis to identify genes highly expressed in this subgroup and constructed a reliable clinical diagnostic model for ccRCC using multiple machine learning algorithms. Furthermore, we identified AXL as a key gene with significant oncogenic activity, where high expression of AXL correlated with poor patient prognosis. Immune infiltration and spatial transcriptomics analyses further revealed that AXL promotes tumor progression interaction with M2 macrophages. Taken together, our analysis establishes a reliable 13-gene panel diagnostic model and AXL gene as reliable biological markers for ccRCC, providing valuable targets and a theoretical foundation for the development of precision-targeted therapies for ccRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsTranscriptomeAlgorithmsAxl Receptor Tyrosine KinaseBiomarkers, TumorEpithelial-Mesenchymal TransitionGene Expression ProfilingGene Expression Regulation, NeoplasticHumansProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesSingle-Cell AnalysisAXL protein, humanAxl Receptor Tyrosine KinaseBiomarkers, TumorProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAXLClear cell renal cell carcinomaMachine learningSingle cell and spatial transcriptomeTumor heterogeneity and plasticity

Identifiers

PMID41029360
PMCPMC12487111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.